Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis - PubMed (original) (raw)

Review

Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis

Anders Rosén et al. Semin Cancer Biol. 2010 Dec.

Abstract

Several types of B cell tumors, particularly MALT lymphomas, are known to have an antigen-driven component in tumor development. Over the past two decades substantial data have accumulated regarding the restricted immunoglobulin (IG) gene repertoire in chronic lymphocytic leukemia (CLL) and its potential implications for antigenic drive in the disease development and progression. Herein we discuss how evidence first illustrated a link between certain B cell receptor (BCR) specificities and disease outcome and the subsequent large-scale IG analyses which revealed the extent of "stereotyped" BCRs in CLL. More recent studies on CLL antibody reactivity have gradually provided clues as to which antigens may be involved in the tumor development. Significantly, CLL monoclonal antibodies have been shown to resemble natural antibodies recognizing molecular motifs both on apoptotic cells (e.g. modified cytoskeletal proteins and oxidation-specific epitopes), as well as exogenous bacteria, indicating that CLL clones possibly arise from B cells which have dual function as scavengers of apoptotic debris, while also having the ability to bind conserved bacterial cell structures. Such revelations have led us to re-evaluate both the phenotypic and functional characteristics of the tumor B cells and the pathway by which CLL arises and develops.

PubMed Disclaimer

Cited by

Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Fraietta JA, Schwab RD, Maus MV. Fraietta JA, et al. Semin Oncol. 2016 Apr;43(2):291-9. doi: 10.1053/j.seminoncol.2016.02.006. Epub 2016 Feb 9. Semin Oncol. 2016. PMID: 27040708 Free PMC article. Review.
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. Riches JC, et al. Blood. 2013 Feb 28;121(9):1612-21. doi: 10.1182/blood-2012-09-457531. Epub 2012 Dec 17. Blood. 2013. PMID: 23247726 Free PMC article.
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.
Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Pérez-Galán P, Wiestner A. Herman SE, et al. Leukemia. 2013 Dec;27(12):2311-21. doi: 10.1038/leu.2013.131. Epub 2013 Apr 26. Leukemia. 2013. PMID: 23619564 Free PMC article.
Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.
Paul A, Edwards J, Pepper C, Mackay S. Paul A, et al. Cells. 2018 Oct 20;7(10):176. doi: 10.3390/cells7100176. Cells. 2018. PMID: 30347849 Free PMC article. Review.
Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma.
Burley TA, Kennedy E, Broad G, Boyd M, Li D, Woo T, West C, Ladikou EE, Ashworth I, Fegan C, Johnston R, Mitchell S, Mackay SP, Pepper AGS, Pepper C. Burley TA, et al. Cancers (Basel). 2022 Mar 15;14(6):1489. doi: 10.3390/cancers14061489. Cancers (Basel). 2022. PMID: 35326640 Free PMC article.

Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis - PubMed (original) (raw)